Our kind sponsors and partners:
At Takeda Oncology, the oncology business unit brand of Takeda Pharmaceutical Company Limited, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.
This singular focus drives our aspiration to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer.
We’ve built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though we’ve made great strides in our fight against cancer, we are determined to do more—to work harder and to reach higher. We continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that we are today.
We know that our mission is not a quick or simple one, but we are up to the task: we aspire to cure cancer.
Boehringer Ingelheim’s oncology research is driven by a passion to advance clinical practice and a determination to improve the lives of patients who are battling cancer. Through our own scientific innovation and partnerships, we are focused on discovering and providing novel best-in-class, breakthrough cancer medications that fit the needs of patients, caregivers and healthcare professionals. We have a clear strategy to become a leader in the field of lung cancer. Boehringer Ingelheim has successfully launched two products globally for non-small-cell lung cancer (NSCLC) that have been widely adopted and established as valuable additions to current clinical practice. Continuous insights and learnings from research and development are key parts of innovation and our way forward to advance clinical practice in lung cancer and other cancer types.
DNB is Norway's largest financial services group and one of the largest in the Nordic region in terms of market capitalization. The Group offers a full range of financial services, including loans, savings, advisory services, insurance and pension products for retail and corporate customers. Within DNB’s international strategy, healthcare is a prioritized area.
DNB is the Nordic Healthcare Bank and a top ranking healthcare bank in the US. The clients are serviced by bankers and industry experts located in New York, Oslo and Stockholm. The company assists international pharma clients with business development by actively monitoring the Nordic early-stage companies for promising technologies/products
Precision for Medicine, Oncology and Rare Disease is the first comprehensive, fully integrated CRO devoted to oncology and rare disease combining this unique experience with Omics, big data + biomarker-guided drug development.
Precision’s uniquely integrated offering enables the science of precision medicine by combining novel clinical trial designs, industry-leading operational and medical experts, advanced biomarker solutions, and an unequivocal passion for rare diseases and oncology. We provide an uncommon array of talent and services to enable our pharmaceutical and life sciences clients to access new advancements, stay ahead of regulatory changes and ultimately achieve their goals faster. The result: a tailored pathway to approval for oncology and rare disease innovators.
The European American Enterprise Council (EAEC) is a private member-driven social enterprise and NETWORK (eight US and EU chapters).